Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 25, 2015 3:34 AM ET


Company Overview of Conatus Pharmaceuticals Inc.

Company Overview

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its products include Emricasan, an orally active pan-caspase protease inhibitor, which is in Phase 2 clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post liver transplant clearance of hepatitis C virus infection with sustained viral response, non-alcoholic steatohepatitis, and nonalcoholic fatty liver disease. The company was founded in 2005 and is headquartered in San Diego, California.

16745 West Bernardo Drive

Suite 200

San Diego, CA 92121

United States

Founded in 2005

25 Employees



Key Executives for Conatus Pharmaceuticals Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 63
Total Annual Compensation: $460.0K
Co-Founder, Chief Scientific Officer and Executive Vice President of Research & Development
Age: 57
Total Annual Compensation: $325.6K
Executive Vice President of Clinical Development
Age: 60
Total Annual Compensation: $94.0K
Compensation as of Fiscal Year 2014.

Conatus Pharmaceuticals Inc. Key Developments

Conatus Pharmaceuticals Inc. Presents at Stifel Healthcare Conference 2015, Nov-18-2015 11:45 AM

Conatus Pharmaceuticals Inc. Presents at Stifel Healthcare Conference 2015, Nov-18-2015 11:45 AM. Venue: The New York Palace Hotel, Hubbard Room, New York, New York, United States. Speakers: Steven J. Mento, Co-Founder, Chief Executive Officer, President and Director.

Conatus Pharmaceuticals Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015; Provides Updates on its Clinical Development Programs

Conatus Pharmaceuticals Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, net loss was $6.1 million or $0.31 per basic and diluted share compared with $6.4 million or $0.42 per basic and diluted share for the third quarter of 2014. For the first nine months of 2015, net loss was $18.1 million or $0.99 per basic and diluted share compared with $17.0 million or $1.10 per basic and diluted share for the first nine months of 2014. The company provided updates on its clinical development programs. Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease and recently reported top-line results from its Phase 2 Portal Hypertension (PH) clinical trial in patients with liver cirrhosis and portal hypertension. Conatus currently has two active Phase 2 clinical trials: POLT-HCV-SVR: in post-orthotopic liver transplant (POLT) recipients with liver fibrosis or cirrhosis post-transplant as a result of recurrent hepatitis C virus (HCV) infection who have successfully achieved a sustained viral response (SVR) following HCV antiviral therapy; and Liver Cirrhosis (LC): in patients with liver cirrhosis and Model for End-stage Liver Disease (MELD) scores of 11 to 18. Conatus announced in September 2015 that the PH clinical trial met the following primary endpoints: a) a clinically meaningful and statistically significant change from baseline in HVPG in patients with liver cirrhosis and severe portal hypertension (HVPG 12 mmHg); and b) a statistically significant change from baseline in cleaved Cytokeratin 18 (cCK18), a mechanism-specific biomarker of excessive cell death that contributes to chronic inflammation, in the total evaluable patient population.

Conatus Pharmaceuticals Inc. to Report Q3, 2015 Results on Nov 04, 2015

Conatus Pharmaceuticals Inc. announced that they will report Q3, 2015 results at 4:30 PM, US Eastern Standard Time on Nov 04, 2015

Similar Private Companies By Industry

Company Name Region
ZymeTx, Inc. United States
Alphagene Inc. United States
Amgen USA Inc. United States
Ionian Technologies, Inc. United States
Celsense, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Conatus Pharmaceuticals Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at